Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
IRVINE, Calif., Feb. 19, 2016 -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, are scheduled to participate at two investor conferences in February. The first conference is the RBC Capital Markets 2016 Global Healthcare Conference in New York City.
| Event: | RBC Capital Markets 2016 Global Healthcare Conference | ||||||
| Date: | Wednesday February 24, 2016 | ||||||
| Time: | 2:35 pm ET | ||||||
| Participant: | Vaseem Mahboob, Chief Financial Officer |
The second conference is the 2016 BTIG MedTech Conference in Snowbird, Utah. This conference will allow institutional investors to meet with the Company but does not include a formal presentation.
| Event: | 2016 BTIG MedTech Conference | ||||||
| Date: | February 24-25, 2016 | ||||||
| Participant: | John McDermott, Chief Executive Officer |
An audio webcast of the Company’s presentation at the RBC Capital Markets 2016 Global Healthcare Conference will be available by visiting the investor relations section of Endologix’s website at www.endologix.com. A replay of the presentation will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com. The Nellix System is an investigational device in the United States.
COMPANY CONTACT: Endologix, Inc. John McDermott, CEO Vaseem Mahboob, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020
